Neurocrine Biosciences Inc (NBIX) stock
NBIXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 2, 2026Score 19/306% below fair value
$162.86−3.06 (-1.84%)
Close on Nov 18, 2026Market cap $16.55BP/E 23.9Yield –
Neurocrine Biosciences market cap
Market capitalization is the share price multiplied by the number of shares outstanding.
Neurocrine Biosciences's market cap was $17.72B on Nov 11, 2026, against $15.17B a year earlier. Over the last 5 years it ranged from $7.49B to $17.72B, with a median of $12.44B.
Market Cap at the end of each year
| Period | Period end | Value | Change |
|---|---|---|---|
| 2026 | Nov 11, 2026 | $17.72B | +25.3% |
| 2025 | Dec 31, 2025 | $14.14B | +2.4% |
| 2024 | Dec 31, 2024 | $13.81B | +6.8% |
| 2023 | Dec 29, 2023 | $12.94B | +12.7% |
| 2022 | Dec 30, 2022 | $11.48B | +42.2% |
| 2021 | Dec 31, 2021 | $8.07B | -9.8% |
| 2020 | Dec 31, 2020 | $8.95B | -9.6% |
| 2019 | Dec 31, 2019 | $9.90B | +52.9% |
| 2018 | Dec 31, 2018 | $6.47B | -5.7% |
| 2017 | Dec 29, 2017 | $6.86B | +104.2% |
| 2016 | Dec 30, 2016 | $3.36B | -30.8% |
| 2015 | Dec 31, 2015 | $4.86B | +186.2% |
| 2014 | Dec 31, 2014 | $1.70B | +169.9% |
| 2013 | Dec 31, 2013 | $628.99M | +26.7% |
| 2012 | Dec 31, 2012 | $496.53M | +5.7% |
| 2011 | Dec 30, 2011 | $469.66M | +57.1% |
| 2010 | Dec 31, 2010 | $299.01M | – |
See a number that looks wrong?